An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Trial Status: active
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety,
tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B
administered orally as monotherapy OR in combination with Hormonal Therapy in subjects
with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV)
breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i
plus hormonal therapy.
Inclusion Criteria
Male or female >/= 18 years old
ECOG Performance Status 0 to 1
Subjects must have histologically or cytologically confirmed diagnosis of ER+, HER2- ABC consistent with ASCO CAP guidelines that is locally advanced and unresectable (Stage III) or metastatic (Stage IV) BC.
Measurable AND evaluable lesions at baseline per RECIST v1.1.
Eligible subjects must meet all of the following criteria:
Progression after receiving 1 line of prior cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) therapy combined with HT in the MBC setting (up to 1 additional line of CDK4/6i is permitted in the post-surgical adjuvant setting);
Subjects must have received therapy for ≥3 months in the MBC setting, or for ≥6 months in the adjuvant setting, prior to progression
Progression after ≤3 lines of prior HT therapy (regardless of whether it is HT alone or in combination with other therapies)
Prior HT combination agents, including SERD, SERM or AI, must have received formal approval by regulatory agency.
≤ 1 prior line of chemotherapy in the metastatic setting
Adequate organ function
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
Presence of visceral metastases with severe organ dysfunction as evidence by signs and symptoms, laboratory studies, lymphangitic spread and/or rapid progression of disease
Pregnant or planning to become pregnant
Prior irradiation to >25% of the bone marrow and/or inadequate bone marrow function or evidence of clinically significant end-organ damage
Major surgery, chemotherapy, targeted therapy, experimental agents, or radiation within 14-28 days prior to Cycle 1, Day 1
Active, serious medical condition that is not well controlled with locally approved medications allowed by the protocol
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in the study
Additional locations may be listed on ClinicalTrials.gov for NCT05304962.
